# Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

> **NCT04884282** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fondazione Ricerca Traslazionale** · enrollment: 105 (estimated)

## Conditions studied

- Metastatic Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Tedopi
- **DRUG:** Nivolumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04884282
- **Lead sponsor:** Fondazione Ricerca Traslazionale
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-12
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04884282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04884282, "Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04884282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*